Contineum Therapeutics (CTNM) Retained Earnings (2023 - 2026)

Contineum Therapeutics' Retained Earnings history runs 4 years deep, the most recent figure standing at $447.2 million for Q2 2026.

• In Q2 2026, Retained Earnings rose 39.46% year-over-year to $447.2 million; the TTM figure through Jun 2026 stood at $447.2 million (up 39.46% YoY), while the FY2025 annual figure was $438.1 million, up 38.91% from the prior year.
• Retained Earnings for Q2 2026 stood at $447.2 million, up from $442.1 million in the prior quarter.
• The five-year high for Retained Earnings was $447.2 million in Q2 2026, with the low at -$83.6 million in Q1 2024.
• The 4-year median for Retained Earnings is $318.0 million (2025), against an average of $280.7 million.
• The sharpest annual moves came in 2024 and 2025: Retained Earnings jumped 519.69% in 2024, then grew 3.38% in 2025.
• Contineum Therapeutics' Retained Earnings stood at -$75.1 million in 2023, then surged by 519.69% to $315.4 million in 2024, then soared by 38.91% to $438.1 million in 2025, then rose by 2.08% to $447.2 million in 2026.
• Business Quant data shows CTNM's Retained Earnings at $447.2 million in Q2 2026, $442.1 million in Q1 2026, and $438.1 million in Q4 2025.